Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters











Publication year range
1.
Toxicol Pathol ; 45(2): 296-301, 2017 02.
Article in English | MEDLINE | ID: mdl-28007014

ABSTRACT

Gastric mucosal injury is frequently observed in nonclinical studies of nonhuman primates. Because microscopic evaluation of stomach is generally a terminal procedure, our objective was to determine whether serum pepsinogen I (PG I) could serve as a noninvasive biomarker for detection of gastric mucosal injury in monkey. Serum PG I was measured using a commercial human immunoassay in cynomolgus monkeys ( n = 166) prior to dosing and/or terminally in 11 studies of up to 1 month duration. Mean ( SD) PG I values (ug/L) for monkeys with ( n = 59) and without ( n = 100) gastric mucosal degeneration were 101 (215) and 28 (12.6), respectively. For monkeys with baseline and terminal PG I data, mean ( SD) fold change (ratio of terminal to baseline PG I) for monkeys with ( n = 57) and without ( n = 76) glandular degeneration were 4.1 (11.3) and 1 (0.28). Receiver operating characteristic area under the curve (AUC) data demonstrated moderate diagnostic accuracy for serum PG I for glandular degeneration, AUC ( SE) 0.789 (0.04), with improved diagnostic accuracy as a fold change of baseline, AUC ( SE) 0.816 (0.04), consistent with the large interindividual but low intraindividual variability of serum PG I values in control monkeys. These data demonstrate that serum PG I is a useful biomarker of drug-induced gastric mucosal injury in the cynomolgus monkey.


Subject(s)
Drug Evaluation, Preclinical/standards , Gastric Mucosa/drug effects , Gastric Mucosa/injuries , Pepsinogen A/blood , Toxicity Tests/standards , Animals , Biomarkers/blood , Drug Evaluation, Preclinical/veterinary , Drug-Related Side Effects and Adverse Reactions/blood , Female , Macaca fascicularis , Male , Retrospective Studies , Toxicity Tests/veterinary
2.
Toxicol Pathol ; 41(6): 921-34, 2013 Aug.
Article in English | MEDLINE | ID: mdl-23334695

ABSTRACT

Hormonally mediated effects on the female reproductive system may manifest as pathologic changes of endocrine-responsive organs and altered reproductive function. Identification of these effects requires proper assessment, which may include investigative studies to profile female reproductive hormones. Here, we briefly describe normal hormonal patterns across the estrous or menstrual cycle and provide general guidance on measuring female reproductive hormones and characterizing hormonal disturbances in nonclinical toxicity studies. Although species used in standard toxicity studies share basic features of reproductive endocrinology, there are important species differences that affect both study design and interpretation of results. Diagnosing female reproductive hormone disturbances can be complicated by many factors, including estrous/menstrual cyclicity, diurnal variation, and age- and stress-related factors. Thus, female reproductive hormonal measurements should not generally be included in first-tier toxicity studies of standard design with groups of unsynchronized intact female animals. Rather, appropriately designed and statistically powered investigative studies are recommended in order to properly identify ovarian and/or pituitary hormone changes and bridge these effects to mechanistic evaluations and safety assessments. This article is intended to provide general considerations and approaches for these types of targeted studies.


Subject(s)
Gonadal Hormones/blood , Gonadotropins, Pituitary/blood , Toxicity Tests/methods , Toxicity Tests/standards , Animals , Dogs , Estradiol/blood , Estrous Cycle/blood , Estrous Cycle/drug effects , Female , Follicle Stimulating Hormone/blood , Genitalia, Female/anatomy & histology , Genitalia, Female/drug effects , Genitalia, Female/physiology , Luteinizing Hormone/blood , Macaca fascicularis , Mice , Progesterone/blood , Rats
3.
Toxicol Pathol ; 40(6 Suppl): 40S-121S, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22949412

ABSTRACT

The INHAND Project (International Harmonization of Nomenclature and Diagnostic Criteria for Lesions in Rats and Mice) is a joint initiative of the Societies of Toxicologic Pathology from Europe (ESTP), Great Britain (BSTP), Japan (JSTP), and North America (STP) to develop an internationally accepted nomenclature for proliferative and nonproliferative lesions in laboratory animals. The purpose of this publication is to provide a standardized nomenclature and differential diagnosis for classifying microscopic lesions observed in the male reproductive system of laboratory rats and mice, with color microphotographs illustrating examples of some lesions. The standardized nomenclature presented in this document is also available for society members electronically on the Internet (http://goreni.org). Sources of material included histopathology databases from government, academia, and industrial laboratories throughout the world. Content includes spontaneous and aging lesions as well as lesions induced by exposure to test materials. A widely accepted and utilized international harmonization of nomenclature for lesions of the male reproductive system in laboratory animals will decrease confusion among regulatory and scientific research organizations in different countries and provide a common language to increase and enrich international exchanges of information among toxicologists and pathologists.


Subject(s)
Biomedical Research/standards , Genital Diseases, Male/pathology , Genitalia, Male/pathology , Terminology as Topic , Animals , Animals, Laboratory , Genital Diseases, Male/classification , Genitalia, Male/chemistry , Genitalia, Male/cytology , Histocytochemistry , Male , Mice , Rats
4.
Toxicol Sci ; 116(2): 397-412, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20466777

ABSTRACT

Nonclinical studies provide the opportunity to anchor biochemical with morphologic findings; however, liver injury is often complex and heterogeneous, confounding the ability to relate biochemical changes with specific patterns of injury. The aim of the current study was to compare diagnostic performance of hepatobiliary markers for specific manifestations of drug-induced liver injury in rat using data collected in a recent hepatic toxicogenomics initiative in which rats (n = 3205) were given 182 different treatments for 4 or 14 days. Diagnostic accuracy of alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (Tbili), serum bile acids (SBA), alkaline phosphatase (ALP), gamma glutamyl transferase (GGT), total cholesterol (Chol), and triglycerides (Trig) was evaluated for specific types of liver histopathology by Receiver Operating Characteristic (ROC) analysis. To assess the relationship between biochemical and morphologic changes in the absence of hepatocellular necrosis, a second ROC analysis was performed on a subset of rats (n = 2504) given treatments (n = 152) that did not cause hepatocellular necrosis. In the initial analysis, ALT, AST, Tbili, and SBA had the greatest diagnostic utility for manifestations of hepatocellular necrosis and biliary injury, with comparable magnitude of area under the ROC curve and serum hepatobiliary marker changes for both. In the absence of hepatocellular necrosis, ALT increases were observed with biochemical or morphologic evidence of cholestasis. In both analyses, diagnostic utility of ALP and GGT for biliary injury was limited; however, ALP had modest diagnostic value for peroxisome proliferation, and ALT, AST, and total Chol had moderate diagnostic utility for phospholipidosis. None of the eight markers evaluated had diagnostic value for manifestations of hypertrophy, cytoplasmic rarefaction, inflammation, or lipidosis.


Subject(s)
Liver/drug effects , Alanine Transaminase/blood , Animals , Area Under Curve , Aspartate Aminotransferases/blood , Biliary Tract/drug effects , Biliary Tract/pathology , Bilirubin/blood , Biomarkers , Cholestasis/chemically induced , Liver/pathology , Male , Necrosis , Rats , Rats, Sprague-Dawley , gamma-Glutamyltransferase/metabolism
5.
Toxicol Pathol ; 36(5): 687-94, 2008 Jul.
Article in English | MEDLINE | ID: mdl-18648097

ABSTRACT

Reduced food consumption and associated lower body weights may occur in subacute toxicity studies. The short-term effects of food restriction (FR) on body and reproductive organ weights, hormones, and testis histology were assessed in Sprague-Dawley rats fed 20% to 36% less (21 g feed/day) than rats fed ad libitum (AL) starting at six, eight, ten, or twelve weeks of age for two or six weeks. Body weight and relative seminal vesicle, ventral prostate, and/or epididymis weights were reduced in rats FR for two or six weeks. Degeneration of stage VII pachytene spermatocytes was seen in rats FR for six weeks when initiated at eight, ten, and twelve weeks of age. Plasma testosterone concentrations were lower in rats FR at ages six to eight weeks, eight to ten weeks, six to twelve weeks, and eight to fourteen weeks. Luteinizing hormone was not statistically different in FR rats compared with AL counterparts. Therefore, duration of lower food intake had a greater impact on spermatogenesis, whereas a younger initial age of lower food intake was more influential on testosterone levels. These interactions are important in the interpretation of subacute toxicology studies employing FR or when test articles lower food consumption relative to AL-fed rats.


Subject(s)
Epididymis/drug effects , Food Deprivation , Prostate/drug effects , Seminal Vesicles/drug effects , Testis/drug effects , Animals , Body Weight/drug effects , Epididymis/pathology , Male , Organ Size/drug effects , Prostate/pathology , Rats , Rats, Sprague-Dawley , Seminal Vesicles/pathology , Spermatocytes/drug effects , Spermatocytes/pathology , Testis/pathology , Testosterone/blood , Time Factors
6.
Toxicol Pathol ; 35(7): 958-71, 2007 Dec.
Article in English | MEDLINE | ID: mdl-18098042

ABSTRACT

Novel vascular lesions were observed in mice given an alpha vbeta 3, alpha vbeta 5 receptor antagonist (SB-273005) for up to 3 months. Vascular smooth muscle cell (VSMC) necrosis was observed in aorta and renal hilar arteries approximately 6 hours after dosing followed by loss of VSMC, adaptive medial thickening by VSMC hypertrophy and deposition of PAS-positive matrix and collagen. Renal hilar and arcuate arteries developed delayed and transient fibrinoid necrosis and inflammation. Vascular regeneration was not evident following drug-withdrawal after 3 days of dosing. Vascular lesions were associated with necrosis, regeneration and fibrosis of heart, kidney and spleen consistent with initial ischemic injury followed by tissue repair. VSMC toxicity was likely not related to integrin antagonism because lesions were not observed with related compounds and no vascular changes were observed in other preclinical species. In vitro studies failed to demonstrate a direct toxic effect of SB-273005 on VSMC or unique species sensitivity of murine VSMC. In conclusion, SB-273005 caused VSMC necrosis in aorta and renal arteries of mice. Lesions did not progress or recover, but there was medial hypertrophic adaptation even with continued dosing. This is considered direct species-specific VSMC toxicity of unknown mechanism and unrelated to vitronectin receptor antagonism.


Subject(s)
Aorta/drug effects , Integrin alphaVbeta3/antagonists & inhibitors , Muscle, Smooth, Vascular/drug effects , Pyridines/toxicity , Renal Artery/drug effects , Animals , Aorta/pathology , Apoptosis/drug effects , Cell Adhesion/drug effects , Cell Survival/drug effects , Cells, Cultured , Female , Heart/drug effects , Immunohistochemistry , Kidney/drug effects , Kidney/pathology , Male , Mice , Mice, Inbred ICR , Microscopy, Electron , Muscle, Smooth, Vascular/pathology , Renal Artery/pathology , Spleen/drug effects , Spleen/pathology
7.
Birth Defects Res B Dev Reprod Toxicol ; 80(3): 225-32, 2007 Jun.
Article in English | MEDLINE | ID: mdl-17570126

ABSTRACT

BACKGROUND: Idoxifene is a selective estrogen receptor modulator similar to tamoxifen but is no longer in pharmaceutical development due to adverse genitourinary effects in the clinic. Histologic observations of the reproductive system and mammary glands are presented from female dogs treated with idoxifene for up to 12 months. METHODS: Studies were conducted as part of regulatory requirements to support clinical development. Idoxifene was given orally by capsule, once daily, for 1, 6, or 12 months to female Beagle dogs (n = 3 or 4/group) aged 11-14 months (start of dosing) at dosages 0, 0.03, 0.3, 1.5, or 3 mg/kg/day. Evaluations included the following: clinical observations, hematology, hemostasis, chemistry, toxicokinetics, and histology. RESULTS: Dose- and time-dependent findings were present in dogs given > or = 0.03 mg/kg/day and included abnormal vaginal discharge, minor increases of platelet and neutrophil counts, and microscopic observations in the ovary (atrophy and mesothelial [ovarian surface epithelium] hyperplasia), endometrium (edema, inflammation, glandular atrophy, squamous metaplasia, increased collagen), myometrium (edema, increased collagen), vagina (squamous hyperplasia, keratinization), and mammary gland (atrophy). CONCLUSION: Dogs given idoxifene exhibited estrogenic effects in ovary, uterus, and vagina but antiestrogenic effects in endometrial and mammary glands consistent with several observations in clinical trials in post-menopausal women treated with triphenylethylenes.


Subject(s)
Estrogen Antagonists/pharmacology , Mammary Glands, Human/drug effects , Ovary/drug effects , Selective Estrogen Receptor Modulators/pharmacology , Uterus/drug effects , Vagina/drug effects , Animals , Dogs , Endometrium/cytology , Endometrium/drug effects , Estrogen Antagonists/therapeutic use , Female , Humans , Mammary Glands, Human/pathology , Ovary/pathology , Tamoxifen/analogs & derivatives , Tamoxifen/pharmacology , Tamoxifen/therapeutic use , Uterus/pathology , Vagina/pathology
8.
Birth Defects Res B Dev Reprod Toxicol ; 80(3): 233-45, 2007 Jun.
Article in English | MEDLINE | ID: mdl-17570128

ABSTRACT

This report describes normal histology of tissues from immature female dogs and sequential microscopic changes that occur during different stages of the estrous cycle in ovary, uterus, vagina and mammary glands. These observations are associated with a literature review of concurrent estrous cycle plasma hormone levels and expression of sex steroid receptors in these tissues. The combined review of different aspects of the estrous cycle in the dog provides readers with a comprehensive presentation and may guide investigators that are involved in testing compounds with hormonal effects in female dogs.


Subject(s)
Dogs/physiology , Estrous Cycle/metabolism , Mammary Glands, Animal/metabolism , Receptors, Estrogen/metabolism , Receptors, Progesterone/metabolism , Animals , Female , Mammary Glands, Animal/cytology , Reproduction/physiology
9.
Article in English | MEDLINE | ID: mdl-17570137

ABSTRACT

Observations associated with drug-induced hyper- or hypoprolactinemia in rat toxicology studies may be similar and include increased ovarian weight due to increased presence of corpora lutea. Hyperprolactinemia may be distinguished if mammary gland hyperplasia with secretion and/or vaginal mucification is observed. Reproductive toxicity study endpoints can differentiate hyper- from hypoprolactinemia based on their differential effects on estrous cycles, mating, and fertility. Although the manifestations of hyper- and hypoprolactinemia in rats generally differ from that in humans, mechanisms of drug-related changes in prolactin synthesis/release can be conserved across species and pathologically increased or decreased prolactin levels may compromise some aspect of reproductive function in all species.


Subject(s)
Prolactin/deficiency , Prolactin/toxicity , Reproduction/drug effects , Animals , Female , Hyperprolactinemia/blood , Prolactin/blood , Rats , Toxicity Tests, Chronic/methods
11.
Cancer Res ; 64(7): 2307-16, 2004 Apr 01.
Article in English | MEDLINE | ID: mdl-15059877

ABSTRACT

Rapid advances in generating new mouse genetic models for lung neoplasia provide a continuous challenge for pathologists and investigators. Frequently, phenotypes of new models either have no precedents or are arbitrarily attributed according to incongruent human and mouse classifications. Thus, comparative characterization and validation of novel models can be difficult. To address these issues, a series of discussions was initiated by a panel of human, veterinary, and experimental pathologists during the Mouse Models of Human Cancers Consortium (NIH/National Cancer Institute) workshop on mouse models of lung cancer held in Boston on June 20-22, 2001. The panel performed a comparative evaluation of 78 cases of mouse and human lung proliferative lesions, and recommended development of a new practical classification scheme that would (a) allow easier comparison between human and mouse lung neoplasms, (b) accommodate newly emerging mouse neoplasms, and (c) address the interpretation of benign and preinvasive lesions of the mouse lung. Subsequent discussions with additional experts in pulmonary pathology resulted in the current proposal of a new classification. It is anticipated that this classification, as well as the complementary digital atlas of virtual histological slides, will help investigators and pathologists in their characterization of new mouse models, as well as stimulate further research aimed at a better understanding of proliferative lesions of the lung.


Subject(s)
Disease Models, Animal , Lung Neoplasms/classification , Mice , Animals , Humans , Lung Neoplasms/pathology
SELECTION OF CITATIONS
SEARCH DETAIL